NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-08-31
Reading BAX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Adjusted EPS near $1.95 in 2026: FY26 EPS guidance $2.05 vs $1.85 target.
Baxter aims for adjusted EPS near $1.95 in 2026. Sales grew 3% in Q1. The company keeps paying a small dividend. It is expanding its operating system for better performance.
Baxter lost $15 million in Q1 2026. Earnings have been volatile with recent misses. Management changes may hurt execution. Growth is slow and profit margins are weak.
The price is about 33% below our fair value near $34. Analysts expect about 2% revenue growth. Our view sees risk in earnings and execution.
Breaks if: Dividend cut or suspension
Breaks if: Adjusted EPS falls below $1.85 in FY26
Breaks if: Significant management departures or failures reported
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on long-term growth. The current thesis state is intact, supported by recent financial results that remain strong relative to industry peers.
The market seems to assume a level of fragility in BAX's execution, given its expensive valuation compared to peers. There is an expectations gap, indicating that while the stock is priced at a premium, the market does not fully reflect the recent strong performance.
Fundamentals are likely to remain stable in the near term, given the low probability of missing earnings expectations. However, management's volatile execution and recent transitions in leadership may introduce some uncertainty.
The long-term thesis hinges on management's ability to maintain and potentially raise guidance, as well as the performance of sector bellwethers that could influence overall healthcare momentum. Additionally, any cuts to guidance could negatively impact sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company reiterated its full-year 2026 financial outlook. It also raised its sales outlook and earnings guidance for 2026. These developments support a positive view on the company's growth objectives.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue growth falls below 2% YoY next year
Continue to implement and expand the Baxter Growth and Performance System as the enterprise operating system for continuous improvement.
Stated as a priority in 3 of last 4 quarters. Management emphasized expansion of the Baxter Growth and Performance System (GPS) with over 230 initiatives launched in 2026-Q1. While financials show improving revenue and operating income from $2.7B and $66M in 2026-Q1 to $2.96B and $217M in 2026-Q2, the GPS priority is a recurring focus with narrow delivery so far.
“Guided by the Baxter Growth and Performance System (GPS), focused on stabilizing the business and continuous improvement.”
“Expanded Baxter Growth and Performance System (GPS) as the enterprise operating system for continuous improvement.”
“Launched more than 230 initiatives under GPS in first quarter, with additional efforts planned throughout 2026.”
Baxter is expanding its GPS as the enterprise operating system for continuous improvement.
Over the next 1 to 3 years, BAX's performance will depend on effective management execution and sector dynamics. Not investment advice.
